论文部分内容阅读
目的探讨前列地尔对2型糖尿病周围神经病变患者疗效及其对血清C反应蛋白(CRP)的影响。方法 90例2型糖尿病周围神经病变患者随机分为两组,对照组40例,治疗组50例,两组均采用常规治疗,对照组加用B1、B12治疗,治疗组加用前列地尔;两组共治疗14d。治疗前后测定血清的CRP。结果经riddi分析,治疗组总疗效明显优于对照组(P<0.05)。治疗组治疗后神经传导速度增加的更显著(P<0.05)。治疗组降低CRP更加明显(P<0.05)。结论前列地尔可以降低2型糖尿病周围神经病变患者CRP的表达,从而改善病情。
Objective To investigate the effect of alprostadil on the patients with type 2 diabetic peripheral neuropathy and its effect on serum C-reactive protein (CRP). Methods Ninety patients with type 2 diabetic peripheral neuropathy were randomly divided into two groups: control group (n = 40) and treatment group (n = 50). The two groups were treated with conventional therapy and the control group with B1 and B12. The treatment group was treated with alprostadil. Two groups were treated for 14 days. Serum CRP was measured before and after treatment. Results by riddi analysis, the total effect of the treatment group was significantly better than the control group (P <0.05). After treatment, the nerve conduction velocity in treatment group increased more significantly (P <0.05). Treatment group decreased CRP more significantly (P <0.05). Conclusion Alprostadil can reduce the expression of CRP in patients with type 2 diabetic peripheral neuropathy so as to improve the condition.